Last reviewed · How we verify
NCT01612650: TOMOSEIN
Assessment of Substitution of Focused Cliches and Ultrasound for Tomosynthesis
NA trial testing tomosynthesis in Breast Cancer in 1,069 participants. Completed in 16 March 2017.
16 March 2017
Quick facts
| Lead sponsor | Centre Oscar Lambret |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | screening |
| Enrollment | 1,069 |
| Start date | 24 February 2012 |
| Primary completion | 16 March 2017 |
| Estimated completion | 16 March 2017 |
| Sites | 4 locations across France |
Drugs / interventions tested
- tomosynthesis
- 2D mammography
Conditions studied
- Breast Cancer — all drugs for Breast Cancer →
- 2D Mammography — all drugs for 2D Mammography →
- 3D Mammography — all drugs for 3D Mammography →
Sponsor
Centre Oscar Lambret — full company profile →
Who can join
40 and older, female only, with Breast Cancer or 2D Mammography. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study aims to assess if using tomosynthesis for breast cancer surveillance will allow a significant decrease of ultrasound cliches (and radiation exposure)
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT01612650
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Breast Cancer
Currently open trials in the same condition.
- NCT06148038 — CBD for Breast Cancer Primary Tumors · Phase 1 · recruiting
- NCT07405801 — A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus R · Phase 2 · recruiting
- NCT07285993 — Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET · Phase 2 · recruiting
- NCT07510698 — Same-Day Awake Mastectomy With Immediate Breast Reconstruction for Patients With Breast Cancer · NA · recruiting
- NCT06768931 — Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer · Phase 2 · recruiting
Other Centre Oscar Lambret trials
Trials by the same sponsor.
- NCT07507773 — Assessment of the Long-term Efficacy of Moderately Hypofractionated Neoadjuvant Radiotherapy Soft Tissue Sarcoma in the · Phase 2 · not yet recruiting
- NCT06807164 — Serratus Plane Block (SPB) Versus Capsaïcine Versus Botox-A for Chronic Neuropathic Pain in Post-mastectomy Syndrome · Phase 2 · recruiting
- NCT06969833 — Prospective Clinico-biological Database of Patients With Ovarian and/or Peritoneal and/or Fallopian Tube Carcinoma · NA · recruiting
- NCT06181201 — Association Between the Composition of the Intestinal Microbiota and Tumor Response in Locally Advanced Rectal Cancer · terminated
- NCT05286684 — Feasibility of Exosome Analysis in Cerebrospinal Fluid During the Diagnostic Workup of Metastatic Meningitis · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT01612650 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Centre Oscar Lambret
- Last refreshed: 23 March 2018
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01612650.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing